CD44v6 Assay Portfolio Service
Aided by in-house scientists and advanced technology platforms, Creative Biolabs is confident in providing an integrated solution for CD44v6 assay services to facilitate your project success.
The Biology of CD44v6
CD44v6 is a transmembrane glycoprotein involved in a variety of biological processes, including cell growth, apoptosis, migration, and angiogenesis, and has been reported to be engaged in the process of cancer development and metastasis.
Functionally, CD44v6 ectodomain interacts with hyaluronic acid (HA) or osteopontin and acts as a coreceptor for a variety of cytokines, such as vascular endothelial growth factor, epidermal growth factor, hepatocyte growth factor. As an important extracellular matrix (ECM) component, HA can promote the phosphorylation of the CD44v6 cytoplasmic domain, which then activates the phosphoinositol-3-kinase /Akt (PI3K/Akt) and MAPK/ERK signaling pathways. Finally, the activation of a series of signaling pathways promotes cell proliferation, migration, and increases the resistance to apoptosis.
Fig.1 The interaction between CD44v6 and HA. (Ma, 2019)
CD44v6 as a Therapeutic Target
Many studies have shown that CD44v6 is highly expressed in a variety of cancers, including breast, gastrointestinal, hepatocellular, colorectal cancer, and neck squamous cell carcinoma. During the last few decades, the therapeutic value of CD44v6 has also been investigated and CD44v6-targeted strategies have been developed used in various cancers. These strategies are applied primarily by preventing the interaction between CD44v6 and HA.
The first therapeutic approach bivatuzumab coupled with the cytotoxic microtubule inhibitor mertansine was an anti-CD44v6 antibody-drug conjugate, which was primarily conducted on patients with head and neck squamous cell carcinoma (HNSCC). In addition, CD44v6 specific peptide, shRNA (short-hairpin RNA), miRNA (microRNA) can also be used to target CD44v6. In preclinical studies, these strategies are effective in limiting cancer progression to varying degrees.
Fig.2 The strategies of anti-CD44v6 therapy. (Ma, 2019)
Our CD44v6 Assay Portfolio Services
To better study the effects of tumor targets and therapeutic errors, Creative Biolabs has developed and optimized a series of functional assay platforms to provide relevant experiments. We are proud to offer one-stop CD44v6 assay portfolio services for global customers to meet your research needs. Our services are characterized by:
-
An excellent expert team for providing real-time technical guidance.
-
Advanced and optimized assay platform to facilitate the data output.
-
Customize experiment types according to customer needs to facilitate project progress.
Creative Biolabs offers high-quality CD44v6 assay portfolio services which will help our clients shorten the research journey. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
-
Ma, L.; et al. CD44v6 engages in colorectal cancer progression. Cell death & disease. 2019, 10(1): 1-3.
For Research Use Only | Not For Clinical Use
Download our brochure